1.Narrative integration and improvement of patients’ quality of life from the perspective of narrative medicine
Xiaolin YANG ; Feng TIAN ; Xia ZHOU
Chinese Medical Ethics 2026;39(2):207-214
“Bio-narrative integration” refers to the process in which a life subject with narrative consciousness actively reviews and reintegrates their life stories, or a subject lacking life and health narrative awareness, with the intervention of healthcare professionals, tells their own life stories and integrates them into a coherent and constantly evolving life narrative process. Starting from the keyword of bio-narrative integration, this paper proposed a classification model of narrative integration. From the perspective of life stages, it was divided into “phasic narrative integration” and “holistic narrative integration.” In terms of integrated narrative style, it was categorized as “positive narrative integration style” and “negative narrative integration style.” Regarding subjective initiative, it was classified as “active narrative integration regulation” and “passive narrative integration regulation.” Then it elaborated the significant value of narrative integration for every life subject, especially in pain relief, the improvement of life resilience, the healthy aging of the elderly, and the ultimate peace of the dying. It was advocated that healthcare practitioners should enhance their professional narrative competence, effectively guide patients to engage in bio-narrative integration regulation, and help them overcome narrative closure, thereby improving the quality of medical care.
2.Investigation of radon activity concentration and dose assessment in subways of Nanning City, China
Xiufang LU ; Yilong MA ; Rongzheng HUANG ; Ziyue LI ; Jiajie LEI ; Lanying FENG ; Zhangfan CHEN ; Xinchun ZHAO
Chinese Journal of Radiological Health 2026;35(1):67-73
Objective To investigate the radon activity concentrations in subways of Nanning City and assess the average annual effective doses for subway staff and passengers due to radon exposure. Methods Sixty-three stations across the subway lines 2, 3, and 5 were selected as study sites. Radon activity concentrations were measured using the scintillation counting method with scintillation vials. Results The radon activity concentrations in subway lines 2, 3, and 5 were 7.9-24.4, 12.0-26.2, and 12.6-18.2 Bq/m3, respectively. The average radon activity concentrations for these three lines were (17.4 ± 4.6), (19.1 ± 4.1), and (14.6 ± 1.7) Bq/m3, respectively. Statistical analysis using SPSS 26.0 software revealed a significant difference in radon activity concentrations among these stations (P<0.01). Considering the data in previous research, the average radon activity concentration across all stations in the subway lines of Nanning City was determined to be 17.4 Bq/m3. The estimated average annual effective dose due to radon exposure was 0.131 mSv for subway staff and 0.033 mSv for passengers. Conclusion The radon activity concentrations in the subway lines of Nanning City were significantly lower than the national standard limit (400 Bq/m3). The annual effective doses from radon exposure for both subway staff and passengers were below the limits specified in the Basic Standards for Protection Against Ionizing Radiation and for the Safety of Radiation Sources (GB18871—2002). The health impact of radon and its progeny on subway staff and passengers in the subway lines of Nanning City was extremely low and can be considered negligible.
3.Construction and application of a system for rational drug use for prescriptions from internet hospitals and external prescriptions and medical insurance fund control based on a pre-review prescription system
Yi GE ; Xiaolan WANG ; Junping HAN ; Bo LYU ; Yu GUAN ; Feng XU ; Aiming SHI
China Pharmacy 2026;37(5):584-588
OBJECTIVE To ensure the safety of patients’ drug use and control the risk of medical insurance expenditure by upgrading the pre-prescription review system to conduct pre-review on prescriptions from internet hospitals and external prescriptions, as well as to review the payment methods of drugs (including in-hospital and external drug dispensing). METHODS The data interfaces of prescriptions from internet hospitals and external prescriptions were integrated to achieve real-time rational drug use intervention. Additionally, an intelligent review project for payment method was added to precisely intervene in the medical insurance payment methods of drugs. The effect of the system upgrade was evaluated by comparing the qualification rates of prescriptions from internet hospitals and external prescriptions and the suspected amounts of drug violations from January to April 2025 (before the system upgrade) and May to August 2025 (after the system upgrade). RESULTS After the upgrade of the pre-prescription review system, the qualification rates of prescriptions from internet hospitals and external prescriptions increased by 3.5% [95% confidence interval (CI)=0.3%-6.7%, P =0.037 ] ; the suspected amounts of drug violations decreased to 52.9% of the pre-upgrade level (95%CI=31.6%-88.5%, P =0.026), and the average monthly sequential decrease was 29.5% (95%CI=12.2%-43.4%, P =0.012). Moreover, the addition of the intelligent review project for payment methods promoted the management of off-label drug use in our hospital. After the upgrade, a total of 79 filling valid applications for off-label drug use were received and archived. CONCLUSIONS The upgrade of the pre-prescription review system effectively improves the review qualification rates of prescriptions from internet hospitals and external prescriptions and the accuracy of medical insurance payment for drugs, and strengthens the supervision of off-label drug use, achieving dual guarantees of clinical rationality and medical insurance compliance.
4.Optimization of drug dispensing and pickup process in traditional Chinese medicine pharmacy based on data-intelligence-driven
Qi WANG ; Panke ZENG ; Haoxin SONG ; Yonggang FENG ; Lili SUN ; Jingting FENG ; Weiqing NIU ; Haiyan DONG ; Feng WANG
China Pharmacy 2026;37(5):660-664
OBJECTIVE To explore the transformation of the dispensing and drug pickup process in traditional Chinese medicine pharmacy (TCM Pharmacy) in our hospital based on data-intelligence-driven, aiming to improve pharmacists’ work efficiency and patients’ drug pickup experience. METHODS Value stream mapping and journey mapping were used to systematically identify non-value-added links in pharmacists’ dispensing process and key pain points in patients’ drug pickup under the traditional process. An intelligent dispensing and drug pickup system for the TCM Pharmacy was developed based on the C# and Android television platforms, and a machine-learning model was adopted to predict patients’ drug pickup waiting time. A comprehensive evaluation was performed from three perspectives: system performance, prediction accuracy, and satisfaction of pharmacists and patients. RESULTS The system successfully streamlined non-value-added links such as “waiting for writing on the board” and “searching for drugs”, and realized multimodal dynamic prompts of dispensing status through auditory (number calling) and visual (television terminal) channels. The constructed model for predicting drug pickup waiting time exhibited good fitting degree and generalization ability (mean absolute error=4.28 min, R 2 =0.882). The comprehensive satisfaction scores of pharmacists and patients in the traditional mode were significantly increased from (70.99±1.74) and (73.58±1.98) to (90.02±1.30) and (88.61±2.08) in the new system, respectively ( P <0.01). CONCLUSIONS The transformation of the intelligent drug dispensing and pickup system for TCM pharmacy based on data-intelligence-driven effectively improves the efficiency of pharmacists’ dispensing work, realizes process transparency and waiting time predictability, and significantly enhances patients’ drug pickup experience.
5.Multidisciplinary comprehensive treatment strategies for pediatric kidney transplantation
Yi FENG ; Yonghua FENG ; Wenjun SHANG
Organ Transplantation 2026;17(2):198-204
As the primary therapy for children with end-stage renal disease, kidney transplantation not only extends life but also profoundly affects growth, psychosocial development and long-term social integration. Due to the unique physiological, immune and drug metabolism characteristics of children, a multidisciplinary treatment strategy is required for pediatric kidney transplantation to ensure the success of transplantation and long-term quality of life. Therefore, the article elaborates in detail on the multidisciplinary collaboration model of pediatric kidney transplantation from the perspectives of the particularity of pediatric kidney transplant recipients, the composition of multidisciplinary collaboration and comprehensive management strategies. It involves close cooperation in multiple fields such as transplant surgery, pediatric nephrology, genetics, pathology, anesthesiology, psychology and nutrition, covering the entire management process from preoperative evaluation, surgical management to long-term postoperative follow-up, in order to provide reference for improving the prognosis of pediatric kidney transplant recipients.
6.Study on seroloy and RHD genotyping of 602 RhD-negative pregnant women and a case of hemolytic jaundice in a neonatal with Del phenotype
Yuli ZHU ; Bin HU ; Zhihui FENG ; Shuxian JIAO
Chinese Journal of Blood Transfusion 2026;39(2):229-235
Objective: To characterize the serological profile, RHD genetic spectrum, and their frequencies among pregnant women preliminary screened as RhD-negative and weak positive in Qingdao and surrounding areas, and correlate these findings with unexpected antibody detection results, thereby providing testing recommendations and suggestions for such individuals. Methods: Blood samples of pregnant women who were initially identified as RhD negative and weak positive in hospitals in Qingdao and surrounding areas over the past five years were collected. Different cloned IgG anti-D antibodies were used for RhD negative confirmation experiments. RHD genotyping was performed by combining PCR-SSP and Sanger sequencing. Unexpected antibody screening and identification were carried out using test tube method and microcolumn gel card. The immunologic status of newborns delivered by anti-D pregnant women was also tracked. Results: A total of 602 blood samples were collected from pregnant women initially identified as RhD-negative and weak positive. Among them, 569 (94.5%) were confirmed as RhD-negative in the RhD confirmation test, and 33 (5.5%) were D variant phenotype. Except for 4 cases where no definite mutations were found, gene analysis revealed 474 (78.7%) D-negative cases with 5 genotypes (RHD
01N.01, RHD
01N.03, RHD
01N.16, RHD
01N.05, and 1 new allele), 90 (15.0%) Del cases with 2 genotypes (RHD
01EL.01, and RHD
01EL.18), 23 (3.8%) weak D cases with 2 genotypes (RHD
15 and 1 new allele), and 11 (1.8%) partial D cases with 2 genotypes (RHD
06.03.01 and RHD
05.04). Anti-D and complex antibodies containing anti-D were detected in 96 RhD-negative and partial D pregnant women (15.9%). After injection of anti-D immunoglobulin, One O-type RhD-negative pregnant woman delivered a newborn with hyperbilirubinemia. The newborn was typed to be B Del, and anti-D was detected in both serum and eluate. Conclusion: The serological profiles, RHD gene types and frequencies among RhD negative pregnant women in Qingdao and surrounding areas are basically consistent with domestic published data. Pregnancy can stimulate anti-D production in D-negative and partial D individuals. However, anti-D antibody has not been detected in Del type pregnant women. Since anti-D immunoglobulin can binds to Del type red blood cells, its administration is not recommended for Del type pregnant women.
7.High-titer anti-IH cold autoantibodies causing abnormal blood agglutination: a case report
Feng LI ; Yanhua ZHANG ; Tianjun LI ; Jin CHE
Chinese Journal of Blood Transfusion 2026;39(2):261-264
Objective: To analyze the causes of abnormal blood agglutination caused by high-titer cold antibodies in blood donors from a serological perspective. Methods: The donor's blood type was identified using the tube method. Direct antiglobulin test (DAT), indirect antiglobulin test (IAT), and antibody titer detection were performed on the samples. Results: The blood type of the donor was type B, and the DAT was negative. No complement components were detected on the surface of the donor's red blood cells. The supernatant of the suspended red blood cells was clear without abnormal coloration, and the agglutinated clumps were intact and difficult to dissociate. The antibody was identified as an IgM-type anti-IH cold agglutinin. At 4℃, this antibody reacted with autologous red blood cells, adult group B red blood cells, adult group O red blood cells, cord blood group B red blood cells and cord blood group O red blood cells, with a stronger reaction intensity observed with group O cells than with B cells. The titers were 512, 128, 256, 32 and 128, respectively. Conclusion: High-titer anti-IH can cause abnormal agglutination of blood at low temperatures. During blood distribution and clinical use, the appearance of blood products shall be strictly inspected to prevent the release of non-conforming blood products.
8.Patient fibrinogen management from a blood transfusion medicine perspective
Chixiang LIU ; Keyuan LAI ; Yuan YAO ; Kuncheng WANG ; Houmei FENG ; Qiusui MAI ; Yinmei LIAO ; Yingsong WU
Chinese Journal of Blood Transfusion 2026;39(2):265-276
From the perspective of transfusion medicine and based on the vision and framework of patient blood management, this article combines the advances in basic science, blood transfusion, laboratory, and clinical medicine. It aims to systematically review the key elements and characteristics of patient fibrinogen management by maintaining and optimizing patients' hemostatic function while reducing blood transfusions. This review enriches the connotation of transfusion medicine, especially patient blood management, and provides valuable insights for clinical practice.
9.Management and practice of ethical review for “amendment” in drug clinical trials
Xingyi LI ; Zhonglin CHEN ; Xingchi QU ; Yu FENG ; Huihui HAN
Chinese Medical Ethics 2026;39(1):58-63
Driven by the growing practical need to accelerate drug development and the continuous innovation of trial design in recent years, the number of protocol amendments during clinical trials have gradually increased, and the changed contents have become more flexible and complex, which significantly heightens the difficulty of ethical review on amendments. Against this backdrop, it is of great importance to fully leverage the role and responsibilities of ethics committees, effectively control clinical trial risks, and ensure subject safety. This paper analyzed development trends of protocol amendments in recent years, sorted out requirements for protocol amendments in Chinese regulations and guiding principles, and examined difficulties of amendment ethical review in practical work. Based on these, targeted strategies and recommendations were proposed, namely, strengthening the integration with scientific review, enhancing the formal review, adjusting the scope of review according to approval notifications, and adopting appropriate review methods, with a view to providing insights and references for the management of the amendment ethical review in drug clinical trials.
10.Issues and recommendations in the implementation of mutual recognition for ethical review outcomes in multicenter clinical research: a case study of 10 contracting institutions in Guangdong province
Xu LU ; Feng CAO ; Xuan DUAN ; Junrong LIU
Chinese Medical Ethics 2026;39(1):64-70
ObjectiveTo investigate the current situation of mutual recognition for ethical review outcomes in multicenter clinical research across 10 contracting medical institutions in Guangdong Province, analyze existing issues and propose improvement recommendations, thereby promoting the standardized management of mutual recognition for ethical review outcomes in medical institutions. MethodsData from 381 multicenter clinical studies conducted in these 10 medical institutions from January 24 to October 31, 2024, were collected. Text visualization was performed using Python and the WordCloud library, and statistical analyses were conducted with SPSS 25.0. ResultsOf the 381 studies investigated, industry-sponsored clinical trials (ISTs) accounted for 51.71%, while investigator-initiated clinical trials (IITs) constituted 48.29%. The proportions of ethical committees serving as primary reviewers and collaborative reviewers were 33.33% and 66.67%, respectively. The confirmation methods of mutual recognition outcomes were primarily expedited reviews (50.66%) and meeting reviews (49.34%), and no cases of “direct confirmation” were found. The Chi-square test revealed statistically significant differences in review confirmation methods based on project type (χ²=14.851, P<0.001) and ethics committee role (χ²= 69.435, P<0.001). The frequency distribution trend of the contingency table showed that IST projects and primary ethics committees preferred to employ meeting review (58.88% and 79.53% respectively, both higher than the average level of 49.34%), while IIT projects and the collaborative ethics committees more frequently utilized expedited review (60.87% and 65.75% respectively, both higher than the average level of 50.66%). ConclusionThe confirmation methods of mutual recognition for ethical review outcomes in multicenter clinical research are significantly associated with the role of the ethics committee and the type of project. It is recommended to improve management systems, enhance information construction and personnel training, as well as clarify mutual recognition responsibilities and strengthen supervision. This aims to ensure review quality while improving mutual recognition efficiency, thereby safeguarding the rights and interests of research participants.

Result Analysis
Print
Save
E-mail